MiMedx Group Inc
MDXG evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MDXG—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MDXG
MiMedx Group Inc is a regenerative medicine company focused on wound and surgical products, with a recent strategic shift away from its late-stage pipeline and toward commercial execution in the Wound and Surgical end markets.
Key risk: Wound sales decline
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 2 clinical trials for MiMedx Group Inc.
MiMedx Group Inc is a regenerative medicine company focused on wound and surgical products, with a recent strategic shift away from its late-stage pipeline and toward commercial execution in the Wound and Surgical end markets.
- Net sales were $64.4M for Q2 2026, a 35% decrease year-over-year driven by a 61% decline in Wound sales, partially offset by 15% growth in Surgical sales [sec_mda · as of 2026-07-29].
- Cash and equivalents stood at $135.8M as of June 30, 2026, with total debt of $17.2M [latest reported financials].
- The company reported a net loss of $14.8M for the six months ended June 30, 2026 [latest reported financials].
- Surgical business posted a sixth consecutive quarter of double-digit year-over-year growth, driven by adoption of AMNIOFIX®, AMNIOEFFECT®, and other products [sec_mda · as of 2026-07-29].
- The company repurchased $12.5M of common stock under its Share Repurchase Plan during Q2 2026 [sec_mda · as of 2026-07-29].
What works
- Surgical business has shown six consecutive quarters of double-digit year-over-year growth, indicating strong commercial traction in that segment [sec_mda · as of 2026-07-29].
- The company has a healthy cash position of $135.8M as of June 30, 2026, providing financial flexibility [latest reported financials].
- Adjusted EBITDA has improved in recent years due to stronger sales growth and expense management [sec · filed 2026-04-29].
What to weigh
- Net sales declined 35% year-over-year in Q2 2026, driven by a 61% drop in Wound sales, highlighting significant headwinds in the core Wound business [sec_mda · as of 2026-07-29].
- The company reported a net loss of $14.8M for the six months ended June 30, 2026, indicating ongoing unprofitability [latest reported financials].
- The reimbursement environment for Wound products remains uncertain, creating headwinds for the company's largest product category [sec · filed 2026-04-29].
From the filings
Quoted directly from source documents.
Surgical business has shown six consecutive quarters of double-digit year-over-year growth.
“These efforts contributed to continued growth in the Surgical business, which demonstrated a sixth consecutive quarter of double-digit year-over-year growth.”
SEC MD&A · July 29, 2026
Net sales declined 35% year-over-year in Q2 2026.
“Net sales were $64 million, a decrease of 35% compared to the prior year period, driven by a 61% decline in Wound sales, partially offset by 15% growth in Surgical sales.”
SEC MD&A · July 29, 2026
The company repurchased $12.5 million of common stock in Q2 2026.
“repurchases of common stock under the Company's Share Repurchase Plan, including $12.5 million of cash paid for repurchases during the second quarter of 2026”
SEC MD&A · July 29, 2026
The company's strategic shift away from Regenerative Medicine and late-stage pipeline.
“shifting the Company's strategy away from Regenerative Medicine and the Company's late stage pipeline, aided by the introduction of EPIEFFECT in the 2nd half of 2023.”
SEC filings · April 29, 2026
Risks & what to watch (4)›
Key risks
- Wound sales decline — Wound sales dropped 61% year-over-year in Q2 2026, indicating significant market or competitive pressures [sec_mda · as of 2026-07-29].
- Reimbursement uncertainty — Medicare reimbursement environment for Wound products remains uncertain, creating headwinds for the company's largest product category [sec · filed 2026-04-29].
- Ongoing net losses — The company reported a net loss of $14.8M for the six months ended June 30, 2026, indicating continued unprofitability [latest reported financials].
- Regulatory and clearance risks — Obtaining regulatory clearances or approvals for biological products or medical devices is costly and time-consuming, and may not be granted [sec · filed 2026-07-29].
What to watch
- Trend in Wound sales recovery or further decline in upcoming quarters [sec_mda · as of 2026-07-29].
- Surgical business growth trajectory and whether double-digit growth can be sustained [sec_mda · as of 2026-07-29].
- Impact of the $5.0 million payment for exclusive distribution rights for RegenKit®‑Wound Gel on future revenue [sec_mda · as of 2026-07-29].
- Share repurchase activity and its effect on capital allocation and shareholder returns [sec_mda · as of 2026-07-29].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run MiMedx Group Inc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MiMedx Group Inc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
46.9 months
D/E 0.30 · 0% dilution
Lead: Approved
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
235
Total value held
$438.5M
| Holder | Shares | Value |
|---|---|---|
| essex woodlands management, inc. | 28,195,249 | $111.4M |
| blackrock, inc. | 11,911,300 | $47.0M |
| vanguard capital management llc | 10,332,012 | $40.8M |
| trigran investments, inc. | 7,175,109 | $28.3M |
| state street corp | 5,056,801 | $20.0M |
| paradigm capital management inc/ny | 3,410,300 | $13.5M |
| renaissance technologies llc | 3,019,871 | $11.9M |
| geode capital management, llc | 2,881,159 | $11.4M |
| dimensional fund advisors lp | 2,694,002 | $10.6M |
| punch & associates investment management, inc. | 2,019,718 | $8.0M |
Showing top 10 of 235 institutional holders of MiMedx Group Inc. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 7.1%
- Days to cover
- 4.9
- Shares short
- 8,389,116
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MDXG short interestGovernance
Frequently asked questions
What is the AI investment thesis for MiMedx Group Inc?
MiMedx Group Inc is a regenerative medicine company focused on wound and surgical products, with a recent strategic shift away from its late-stage pipeline and toward commercial execution in the Wound and Surgical end markets.
What is MiMedx Group Inc's lead drug candidate?
MiMedx Group Inc's most advanced tracked candidate is AMNIOFIX (Approved) for Liver Transplant.
Who is the CEO of MiMedx Group Inc?
Mr. Joseph H. Capper is the chief executive officer of MiMedx Group Inc (MDXG).
Where is MiMedx Group Inc headquartered?
MiMedx Group Inc (MDXG) is headquartered in Marietta, GA, United States.
What therapeutic areas does MiMedx Group Inc focus on?
MiMedx Group Inc develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.